10-K: ADMA Biologics Reports Strong 2025 Operational Growth

ADMA Biologics achieved significant revenue and gross profit growth in 2025, driven by strong ASCENIV sales and manufacturing efficiencies, despite a reported net income decrease influenced by a prior-year tax benefit.

Summary

• Total revenues increased by 20% to $510.2 million in 2025, up from $426.5 million in 2024.
• Gross profit rose to $292.8 million in 2025, compared to $219.6 million in 2024, with gross margin improving to 57.4% from 51.5%.
• ASCENIV sales surged by 51% to $362.5 million in 2025, reflecting increased physician, payer, and patient acceptance.
• The FDA approved an innovative yield enhancement production process in April 2025, expected to increase ASCENIV and BIVIGAM production yields by 20% or more, supporting sustained margin expansion in 2026.
• Net income for 2025 was $146.9 million, a decrease from $197.7 million in 2024, primarily due to a non-recurring deferred tax benefit in 2024.
• Adjusted EBITDA increased by $66.4 million to $231.0 million in 2025, demonstrating strong operational performance.
• The company divested three plasma collection centers for $12.0 million in December 2025, shifting to a more capital-efficient supply model and securing long-term plasma supply agreements.
• A supplemental Biologics License Application (sBLA) was filed in June 2025 to expand ASCENIV's label to include pediatric patients two years and older, with potential FDA approval in the first half of fiscal year 2026.
• Development of SG-001, an S. pneumonia hyperimmune globulin, is progressing with a pre-Investigational New Drug (IND) package anticipated for submission to the FDA in fiscal year 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive report, reflecting robust operational growth, significant margin expansion, and strategic advancements in product development and supply chain management. The strong performance of ASCENIV and the anticipated benefits from yield enhancement and AI initiatives position the company favorably, despite a reported net income dip influenced by a non-recurring tax benefit in the prior year.

Positives

• Total revenues increased by 20% to $510.2 million in 2025, from $426.5 million in 2024.
• Gross profit increased to $292.8 million in 2025, up from $219.6 million in 2024, with gross margin improving to 57.4% from 51.5%.
• ASCENIV sales grew by 51% to $362.5 million in 2025, driven by increased market acceptance and utilization.
• FDA approval of the yield enhancement production process in April 2025 is expected to increase ASCENIV and BIVIGAM production yields by 20% or more, leading to sustained margin expansion.
• Adjusted EBITDA improved by $66.4 million to $231.0 million in 2025, reflecting strong operational performance.
• The divestiture of three plasma collection centers for $12.0 million and associated long-term supply agreements are expected to deliver accretive cost savings, improve capital efficiency, and ensure durable plasma supply through the late 2030s.
• The One Big Beautiful Bill Act (OBBBA) enacted in July 2025 permanently eliminated the requirement to capitalize and amortize U.S.-based research and experimental expenditures, reducing current income tax liabilities.
• Acquisition of real estate in Boca Raton, FL for $12.6 million in July 2025 allows for expansion of production operations and provides storage redundancies.
• Successful initial use and expansion of the ADMAlytics AI program in supply chain, production, and commercial operations is expected to enhance efficiency and growth.
• Submission of a sBLA for ASCENIV's label expansion to include pediatric patients (two years and older) in June 2025, with anticipated FDA approval in the first half of 2026.
• Progress in the SG-001 pipeline program, including successful pilot-scale batch production and ongoing animal studies, with a pre-IND package anticipated in fiscal year 2026.

Negatives

• Net income decreased to $146.9 million in 2025 from $197.7 million in 2024, primarily due to a non-recurring deferred tax benefit in 2024.
• Sales of BIVIGAM decreased by 14% to $122.0 million in 2025.
• Sales of intermediates and other products decreased by 75% to $8.6 million in 2025.
• Voluntary withdrawal of three lots of BIVIGAM in 2025 resulted in a $4.0 million reduction in revenue due to customer credits.
• Selling, general and administrative expenses increased by 24% to $91.6 million in 2025, driven by higher compensation costs, insurance premiums, professional fees, and software expenses.
• Loss on extinguishment of debt increased to $3.3 million in 2025 from $1.2 million in 2024 due to prepayment penalties and write-offs related to the Ares Credit Facility.
• The company incurred a one-time, non-recurring charge of $2.1 million in 2023 for discarding two in-process BIVIGAM production batches due to an IT systems disruption, which also adversely impacted plasma center operating expenses by $0.7 million.

Risks

• Inability to maintain profitability and continue generating positive cash flows in the future, despite recent net income.
• Reliance on third parties for filling, packaging, testing, labeling, and source plasma, which may lead to delays, insufficient quantities, or non-compliance.
• Inaccuracy of market opportunity estimates and revenue growth forecasts, potentially leading to failure to grow at anticipated rates.
• Periodic inspections by the FDA and other regulatory authorities, which could result in enforcement actions, product recalls, or operational disruptions.
• Business interruptions due to natural disasters, power loss, equipment failure, cyberattacks, human error, global health occurrences, or geopolitical conditions.
• Issues in the development and use of AI (ADMAlytics) potentially resulting in reputational harm and increased liability exposure if it fails to perform as intended or produces unreliable outputs.
• Limited ability to market or seek approval for ASCENIV for alternative indications without additional successful clinical trials and FDA approval.
• Challenges in balancing research and development activities with commercialization efforts, including procuring adequate supply of high-titer RSV plasma.
• Inability to successfully expand manufacturing processes or increase production capabilities, including obtaining requisite FDA approval for new equipment.
• Potential for products to be subject to post-marketing restrictions or withdrawal from the market, and substantial penalties for non-compliance with regulatory requirements.
• Historical reliance on a few key customers (BioCare, CuraScript) for a significant portion of total revenue and accounts receivable, with the loss of any potentially having a material adverse effect.
• Product quality and compliance issues leading to regulatory actions, loss of customer confidence, and financial impact.
• Lack of acceptance and use of current or future products by physicians, payers, and patients, impairing revenue generation.
• Accruals for U.S. Medicaid rebates and other liabilities being estimates subject to change, potentially impacting financial results.
• Long-term success depending on new product development or acquisition, with failure impacting profitability.
• Exposure to consumer and health privacy laws (HIPAA, CCPA, CPRA) due to plasma donor information collection, creating enforcement and litigation risks.
• JPM Credit Facilities being subject to acceleration in specified circumstances, potentially leading to creditors taking possession of collateral.
• Developments by competitors rendering products or technologies obsolete or non-competitive.
• Inability to protect patents, trade secrets, or other proprietary rights, or challenges to existing patents, potentially damaging competitiveness.
• Risk of infringing third-party patents, leading to prohibitions on manufacturing/commercialization or costly licensing/redesign efforts.
• Inability to successfully manage growth, straining management and resources.
• Loss of one or more key members of the management team adversely affecting business.
• Cyberattacks and other security breaches compromising proprietary information, disrupting operations, or damaging reputation.
• Dependence on the safety of plasma supply, third-party testing, and manufacturing processes to counter transmittable diseases.
• Supply constraints if adequate quantities of FDA-approved source and high-titer plasma or other raw materials cannot be obtained.
• Limitations on the ability to use net operating loss carryforwards (NOLs) due to ownership changes, increasing tax liabilities.
• Volatility of operating results and financial condition due to fluctuations in tax obligations, effective tax rates, and realization of net deferred tax assets.
• Volatility in the market price of common stock, disproportionate to operating performance, due to various internal and external factors.
• Sales of a substantial number of shares of common stock, or the perception of such sales, adversely affecting the market price.
• Provisions in corporate documents and Delaware law discouraging, delaying, or preventing a change in control or management.
• No intention to pay cash dividends in the foreseeable future, making capital appreciation the sole source of gain for investors.
• Risk of delisting from Nasdaq if strict listing requirements are not met.
• Board's ability to issue and fix terms of preferred stock and additional common stock without stockholder approval, adversely affecting common stock holders' rights.
• Potential adverse effects from geopolitical and economic conditions, war, terrorism, or other military actions on supply chain, customer orders, and capital markets.
• Inadequate funding for the FDA, SEC, and other government agencies hindering regulatory approvals and access to capital.
• Changes in legal and regulatory requirements, including reduced judicial deference to administrative agencies, impacting operations and future prospects.
• Manufacturing processes for plasma-based biologics being complex and susceptible to contamination and impurities, leading to product write-offs or recalls.

Future Outlook

The company anticipates continued rapid growth for ASCENIV throughout fiscal year 2026 and beyond, supported by its first full year of yield-enhanced production, which is expected to drive sustained margin expansion. Fiscal year 2026 and 2027 projected annual revenues for IG products are greater than $635 million and $775 million, respectively, with Adjusted Net Income exceeding $255 million and $315 million, and Adjusted EBITDA exceeding $360 million and $455 million, respectively. The company expects to continue hiring additional full-time employees across various departments and anticipates total 2026 capital expenditures between $22.0 million and $27.0 million. The company believes its current cash, cash equivalents, accounts receivable, and projected operating cash flow will be sufficient to fund operations through the first quarter of 2027 and beyond, not anticipating the need for additional capital at this time.

Management Comments

• Management believes the Boca Facility, based on current production yields and ongoing supply chain enhancements, has the potential to produce sufficient quantities of IG products representing projected annual revenues greater than $635 million in 2026 and $775 million in 2027.
• Management believes the innovative yield enhancement process, which increases ASCENIV and BIVIGAM production yields by 20% or more, will support anticipated sustained margin expansion in fiscal year 2026, its first full year of yield-enhanced production.
• Management expects ASCENIV's rapid growth to continue throughout fiscal year 2026 and beyond, driven by expanding prescriber and patient base and record utilization.
• Management believes the strategic divestiture of plasma collection centers and new long-term supply agreements reflect a shift toward a more flexible, capital-efficient supply model, expected to deliver accretive cost savings and durable plasma supply confidence through the late 2030s.
• Management anticipates potential FDA approval of the sBLA for ASCENIV's pediatric label expansion in the first half of fiscal year 2026.
• Management anticipates submitting a pre-Investigational New Drug (IND) package to the FDA for SG-001 in fiscal year 2026, potentially enabling direct progression into a registrational clinical trial.
• Management estimates that an S. pneumonia hyperimmune globulin (SG-001), if approved, has the potential to generate peak annual revenue of $300-500 million.
• Management believes its existing ADMA BioCenters facilities are currently in compliance with state and industry standards.

Industry Context

StockSavvy.ai notes that ADMA Biologics operates within the highly competitive and technologically evolving biopharmaceutical industry, specifically in the plasma products market. The U.S. sales of immune and hyperimmune globulin products were approximately $13 billion in 2024 and are expected to exceed $30 billion by 2033, indicating a robust and growing market. ADMA's focus on specialty biologics for immunodeficient patients positions it within a segment with significant unmet needs. The company faces competition from major global players like CSL Behring, Grifols, Takeda, Octapharma, and BPL/Kedrion, which often have greater resources. The industry is also seeing the emergence of non-plasma therapies, such as anti-FcRn inhibitors, which could disrupt traditional IVIG usage for certain indications like Myasthenia Gravis, CIDP, ITP, and Pemphigus Vulgaris. ADMA's strategic moves, including yield enhancement, AI implementation, and pipeline development (SG-001), are critical for maintaining competitiveness and capturing market share in this dynamic environment.

Comparison to Industry Standards

• ADMA Biologics' projected annual revenues for IG products of over $635 million in 2026 and $775 million in 2027, along with Adjusted EBITDA exceeding $360 million and $455 million, demonstrate strong growth potential within the broader immune and hyperimmune globulin market, which is expected to grow from $13 billion in 2024 to over $30 billion by 2033.
• The company's gross margin of 57.4% in 2025, improving from 51.5% in 2024, indicates strong manufacturing efficiency and product mix compared to general pharmaceutical industry benchmarks, which can vary widely but often see gross margins in the 70-80% range for branded specialty drugs, suggesting room for further optimization but solid performance for biologics.
• ADMA's reliance on a limited number of third-party contractors for fill/finish and plasma supply, while common in the biologics industry, exposes it to risks similar to those faced by smaller players compared to integrated giants like CSL Behring or Grifols, who have extensive internal supply chains.
• The development of SG-001, an S. pneumonia hyperimmune globulin with a potential peak annual revenue of $300-500 million, positions ADMA to compete in a specific niche against existing anti-infective therapies and vaccines, addressing documented anti-infective resistance and vaccine-naive populations, similar to how other hyperimmune products (e.g., Hepatitis B, tetanus) target specific high-risk groups.
• The implementation of ADMAlytics, an AI program for supply chain and production, aligns with broader industry trends of leveraging advanced analytics to improve operational efficiencies, a strategy increasingly adopted by both large and small biopharmaceutical companies to optimize complex manufacturing processes.

Management Changes

Corporate Governance

Legal Proceedings

• Neither the company nor its subsidiaries are a party to any material pending legal proceedings, other than ordinary routine litigation incidental to the business.

Related Party Transactions

• The company leases an office building and equipment from Areth, LLC, a company controlled by Dr. Jerrold B. Grossman (Vice Chairman) and Adam S. Grossman (President and CEO), paying monthly rent of $10,000. The agreement was extended to December 31, 2026.
• The company purchased specialized equipment and repair services from GenesisBPS and its affiliates, which was owned by Dr. Grossman and Adam Grossman until September 30, 2025. Purchases amounted to $0.1 million in 2025, $0.2 million in 2024, and $0.4 million in 2023.

Stakeholder Impact

• **Shareholders:** Potential for increased shareholder value through the share repurchase program, strong revenue and gross profit growth, and pipeline advancements. However, potential for dilution from future equity raises and stock price volatility remain.
• **Employees:** Continued hiring and investment in employee development, health, and safety programs. Increased headcount to support business growth, but also subject to cybersecurity training and insider trading policies.
• **Customers:** Continued availability of ASCENIV, BIVIGAM, and Nabi-HB, with improved production yields and expanded distribution. Voluntary withdrawal of BIVIGAM lots impacted some customers, but the issue is believed to be resolved.
• **Suppliers:** Continued reliance on third-party plasma suppliers (Grifols, KEDPlasma) and contract manufacturers, with new long-term agreements diversifying supply base and ensuring confidence.
• **Creditors:** Refinancing of senior debt with JPM Credit Facilities provides a more stable capital structure, but obligations are secured by substantially all assets and subject to financial covenants.

Next Steps

• Continue to expand the commercial production and distribution network for IG products, focusing on shifting revenue mix towards ASCENIV.
• Expand ASCENIV's FDA-approved uses, leveraging clinical trial data and real-world outcomes.
• Improve the Boca Facility's and ADMA BioCenters' supply, operating efficiencies, yields, and gross margins, with fiscal year 2026 being the first full year of yield-enhanced production.
• Continue to broadly implement and optimize the ADMAlytics AI program across supply chain, production, and commercial operations.
• Seek potential FDA approval for ASCENIV's sBLA for pediatric patients in the first half of fiscal year 2026.
• Expand and develop the pipeline with additional specialty plasma and/or hyperimmune immunoglobulin products, including submitting a pre-IND package for SG-001 to the FDA in fiscal year 2026.
• Complete the sale of the remaining plasma collection center (Laurel Center) in the first quarter of 2026.
• Hire additional full-time employees devoted to compliance, production, quality assurance, quality control, plasma collection and processing, sales, medical and scientific affairs, and administration.

Key Dates

Recommendation

ADMA Biologics demonstrates robust operational performance with significant revenue and gross profit growth, driven by strong market acceptance of ASCENIV. The FDA approval of the yield enhancement process and the strategic plasma center divestiture are expected to further boost margins and capital efficiency. The company's pipeline, particularly SG-001, offers substantial future revenue potential. While reported net income was lower due to a non-recurring tax benefit in the prior year, underlying operational metrics (Adjusted EBITDA, Adjusted Net Income) show strong improvement. The share repurchase program signals management's confidence. These factors, combined with a clear growth strategy and effective risk management, make ADMA Biologics a compelling 'strong buy' for long-term investors.

Keywords

Biopharmaceutical, Plasma-derived therapeutics, Immunoglobulin, IVIG, ASCENIV, BIVIGAM, Nabi-HB, Primary Humoral Immunodeficiency, PIDD, RSV, S. pneumoniae, Plasma collection, FDA approval, Yield enhancement, Biologics License Application, cGMP, ADMAlytics, Biologics, Healthcare, Specialty biologics